<DOC>
	<DOCNO>NCT01850615</DOCNO>
	<brief_summary>This trial conduct Asia , Europe , South America , United States America ( USA ) . The aim trial investigate efficacy safety FIAsp basal-bolus regimen versus basal insulin therapy , combination metformin adult subject type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Safety FIAsp Basal-bolus Regimen Versus Basal Insulin Therapy , Both Combination With Metformin Adult Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 diabetes ( diagnose clinically ) least 6 month prior screen visit ( Visit 1 ) Current treatment daily insulin detemir , insulin glargine human isophane insulin , NPH least 3 month prior screen visit ( Visit 1 ) Current treatment ) metformin unchanged dose least 3 month prior screen ( visit 1 ) . The metformin dose must least 1000 mg b ) metformin combination sulfonylurea ( SU ) glinide Dipeptidyl peptidaseIV inhibitor and/or alphaglucosidase inhibitor ( AGI ) unchanged dose least 3 month prior screen ( visit 1 ) . The metformin dose must least 1000 mg HbA1c central laboratory ) 7.59.5 % ( 58 80 mmol/mol ) ( inclusive ) metformin group screen visit ( Visit 1 ) b ) 7.59.0 % ( 58 75 mmol/mol ) ( inclusive ) metformin + oral antidiabetic drug ( OAD ) ( sulphonylurea ( SU ) , glinide , dipeptidyl peptidaseIV ( DDPIV ) inhibitor , alphaglucosidase inhibitor ( AGI ) combination group screen visit ( Visit 1 ) Body mass index ( BMI ) equal less 40.0 kg/m^2 Any use bolus insulin , except shortterm use due intermittent illness ( long 14 day consecutive treatment ) within 3 month prior screen visit ( Visit 1 ) Use Glucagonlike peptide1 ( GLP1 ) agonists and/or Thiazolidinediones ( TZD ) within last 3 month prior screen ( visit 1 ) Recurrent severe hypoglycaemia ( one severe hypoglycaemic event last 12 month ) hypoglycaemic unawareness judge Investigator , hospitalisation diabetic ketoacidosis previous 6 month prior screen ( Visit 1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>